Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Roche picks up European rights to diabetes implant

Will distribute Senseonics' Eversense CGM System in Germany, Italy and the Netherlands

Roche Eversense CGM Senseonics 

Roche's diabetes business has acquired distribution rights to an implantable long-term continuous glucose monitoring (CGM) system.

It will commercialise Senseonics' Eversense CGM system, selling the implant to diabetes patients and clinics in Germany, Italy and the Netherlands, with an options to expand the deal to further countries and products in the future.

The Eversense combines a small sensor that works for us to 90 days, a wearable and removable smart transmitter and mobile application, and seeks to replace the weekly CGM systems currently on the market.

The Eversense sensor is inserted below the patient's skin and uses flurorescence sensing technology to communicate with the smart transmitter, which then wirelessly sends blood glucose levels to the mobile app.

Tim Goodnow, CEO and president of Senseonics, said: “Together with Roche's market presence, and extensive sales and support network, we aim to deliver a truly innovative continuous, long-term glucose monitoring solution to millions of people with diabetes.”

Goodnow's company will retain responsibility for product development, regulatory approval, quality management, and manufacturing while Roche will take on sales, marketing, customer support and distribution activities in the agreement's territories.

The Maryland, US-based medical technology company's deal with Roche follows its agreement with Rubin Medical, which has the rights to market the Eversense system in Sweden, and follows soon after a tie-up between Medtronic and Qualcomm for a new range of diabetes sensors.

Meanwhile, Senseonics last month won a European Kitemark for the Eversense system, confirming it meets the European Commission's Essential Requirements of the Active Implantable Medical Device Directive.

2nd June 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics